株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

抗体-薬物複合体(ADC):治験追跡調査

Antibody Drug Conjugates: Clinical Trial Tracker

発行 ROOTS ANALYSIS 商品コード 289451
出版日 ページ情報 英文
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.81円で換算しております。
Back to Top
抗体-薬物複合体(ADC):治験追跡調査 Antibody Drug Conjugates: Clinical Trial Tracker
出版日: 2013年11月06日 ページ情報: 英文
概要

抗体-薬物複合体(ADC)は治療薬の新しいクラスであり、大小の製薬企業どちらからも関心を集めています。一般に抗体と毒性薬物/化学療法薬の結合として取り組まれ、これらの複合体は病気の治療をより効率的かつ効果的にすると考えられています。

当レポートでは、抗体-薬物複合体(ADC)の領域で現在実施されている様々な治験および前臨床試験について詳細に分析しており、今後10年間のADC市場の予測、産業のSWOT分析、ADC市場に登場するキープレイヤーのひとつ、CMO(医薬品製造受託機関)に関するケーススタディを取り上げ、概略下記の構成で取り上げております。

イントロダクション・パイプライン詳細

  • 第1章 市場概要
  • 第2章 ダッシュボード:パイプライン分析
  • 第3章 臨床開発における分子:治験詳細
  • 第4章 前臨床開発における分子:治験詳細

市場予測

  • 第5章 市場予測:前提条件
  • 第6章 市場予測:詳細
  • 第7章 比較予測シナリオ

産業分析

  • 第8章 産業SWOT分析
  • 第9章 ケーススタディ:ADCにおける請負製造
目次
Product Code: CT10001

The primary objective of this report is to capture details on the various clinical and preclinical trials which are currently underway in the field of Antibody Drug Conjugates. We have identified a number of such trials which are taking place for a variety of indications across multiple geographies. For each specific trial, we have provided the following information:

  • 1. Trial Objective
  • 2. Manufacturer / Licensee
  • 3. Technology Provider
  • 4. Antibody
  • 5. Cytotoxin
  • 6. Linker
  • 7. Type of Cancer
  • 8. Indication
  • 9. Sponsor / Collaborator
  • 10. Trial Phase
  • 11. Trial Status
  • 12. Start Date
  • 13. End Date
  • 14. Enrolment
  • 15. Age Group
  • 16. Inclusion Criteria
  • 17. Exclusion Criteria
  • 18. Study Design
  • 19. Primary Endpoint
  • 20. Secondary Endpoint
  • 21. Treatment Arms
  • 22. Route of Administration
  • 23. Location(s)
  • 24. Trial Results (if known)

The above information has also been presented in the form a dashboard to provide a high level quick overview of the ongoing activity in this space.

In addition to the clinical trial details, the report also provides the following:

  • Detailed forecasts of the ADC market over the course of next ten years. Owing to the niche nature of this market, we have presented three scenarios to add robustness to our market forecast. The conservative, base and optimistic scenarios represent three different tracks of industry evolution.
  • Industry SWOT analysis summarising the challenges as well as opportunities in the market for different stakeholders.
  • A case study on CMOs , one of the key players in emergence of the ADC market

Research Methodology

Most of the data presented in this report has been gathered by secondary research. We have also conducted interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will shape up across different regions and drug segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Other analysts' opinion reports

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Table of Contents

Introduction and Pipeline Details

  • Section 1. Market Overview
  • Section 2. Dashboard: Pipeline Analysis
  • Section 3. Molecules in Clinical Development: Trial Details
  • Section 4. Molecules in Preclinical Development: Trial Details

Market Forecast, 2013 - 2023

  • Section 5. Market Forecast: Assumptions
  • Section 6. Market Forecast: Details
  • Section 7. Comparative Forecast Scenarios

Industry Analysis

  • Section 8. Industry SWOT Analysis
  • Section 9. Case Study: Contract Manufacturing in ADCs

List of Figures

Pipeline Details

  • Figure 1: ADCs in Clinical Development: Distribution by Companies
  • Figure 2: ADCs in Clinical Development: Distribution by Highest Phase of Development
  • Figure 3: ADCs in Clinical Development: Distribution by Type of Antibody
  • Figure 4: ADCs in Clinical Development: Distribution by Type of Cytotoxin
  • Figure 5: ADC Clinical Trials: Distribution by Phase of Development
  • Figure 6: ADC Clinical Trials: Distribution by Trial Status
  • Figure 7: ADC Clinical Trials: Distribution by Sponsor Type
  • Figure 8: ADC Clinical Trials: Distribution by Cancer Type
  • Figure 9: ADCs in Preclinical Development: Distribution by Companies

Market Forecast

  • Figure 10: ADC Market Forecast, Base Scenario (USD MM)
  • Figure 11: ADC Market Forecast, Scenario Comparison (USD MM)

List of Tables

Pipeline Details

  • Table 1: Molecules in Clinical Development: Pipeline Details
  • Table 2: Molecules in Preclinical Development: Pipeline Details

Market Forecast

  • Table 3: Expected Launch Year of ADCs in Clinical Development

Industry Analysis

  • Table 4: SWOT Analysis
  • Table 5: Contract Manufacturers and Their Capabilities

List of Companies

The following companies and organisations have been mentioned in the report:

  • 1.Abbvie
  • 2.ADC Therapeutics
  • 3.Agensys
  • 4.Allozyne
  • 5.Ambrx
  • 6.Amgen
  • 7.AvidBiologics
  • 8.Bayer
  • 9.Beth Israel Deaconess Medical Center
  • 10.Biogen Idec
  • 11.Biotest AG
  • 12.Bristol-Myers Squibb
  • 13.British Columbia Cancer Agency
  • 14.Cancer Research UK
  • 15.Celldex Therapeutics
  • 16.Centocor (now Janssen Biotech)
  • 17.CytomX Therapeutics
  • 18.Daiichi Sankyo
  • 19.Dana-Farber Cancer Institute
  • 20.Endo Pharmaceuticals
  • 21.European Organisation for Research and Treatment of Cancer (EORTC)
  • 22.Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
  • 23.Fondazione Michelangelo
  • 24.Foundation for the National Institutes of Health
  • 25.Fred Hutchinson Cancer Research Center
  • 26.Genentech
  • 27.Genmab
  • 28.GlaxoSmithKline
  • 29.H. Lee Moffitt Cancer Center and Research Institute
  • 30.Heidelberg Pharma
  • 31.ImmunoGen
  • 32.Immunomedics
  • 33.Intellect Neurosciences
  • 34.Italian Lymphoma Foundation
  • 35.Jules Bordet Institute
  • 36.M.D. Anderson Cancer Center
  • 37.Massachusetts General Hospital
  • 38.MediaPharma
  • 39.Memorial Sloan-Kettering Cancer Center
  • 40.Mersana Therapeutics
  • 41.Millennium Pharmaceuticals
  • 42.MorphoSys
  • 43.National Cancer Institute (NCI)
  • 44.National Research Council, Canada
  • 45.National Surgical Adjuvant Breast and Bowel Project (NSABP)
  • 46.Northwestern University
  • 47.Oncology Institute of Southern Switzerland
  • 48.Oxford Biotherapeutics
  • 49.Pfizer
  • 50.Philochem
  • 51.Princess Margaret Hospital, Canada
  • 52.Progenics Pharmaceuticals
  • 53.Robert H. Lurie Cancer Center
  • 54.Roche
  • 55.Sanofi
  • 56.Seattle Genetics
  • 57.Sidney Kimmel Comprehensive Cancer Center
  • 58.Southwest Oncology Group
  • 59.Spirogen
  • 60.St. Jude Children's Research Hospital
  • 61.Stanford University
  • 62.Stem CentRx
  • 63.Swiss Group for Clinical Cancer Research
  • 64.Synthon Biopharmaceuticals
  • 65.The Lymphoma Academic Research Organisation
  • 66.UCB
  • 67.UNC Lineberger Comprehensive Cancer Center
  • 68.University College, London
  • 69.University of Birmingham
  • 70.University of Cologne
  • 71.University of Washington
  • 72.VivaMab
  • 73.Viventia Biotechnologies
  • 74.Washington Hospital Center
  • 75.Washington University School of Medicine
  • 76.West German Study Group
  • 77.Wyeth
  • 78.Zhejiang Medicine Co. Ltd. (ZMC)
  • 79.Zymeworks
Back to Top